Fig. 1

Flow Diagram. Among 1418 patients with rheumatoid arthritis followed by a primary care physician, 1056 were eligible for screening and 539 received screening. Among those with orders for lipids, 290 had complete lipid panels for analysis after excluding those with contraindications to therapy. *Contraindications to therapy included pregnancy (N = 5), myopathy (N = 2), liver disease (e.g. cirrhosis, liver cancer, alcoholic liver disease, hepatitis C, hepatitis B) (N = 16) or interacting medications including erythromycin, protease inhibitors, itraconazole, and clarithromycin (N = 8). Abbreviations: RA = rheumatoid arthritis, LDL = low density lipoprotein, LLT = lipid lowering therapy